At the end of the third quarterly report, the head enterprises on the pharmaceutical subdivision track are more gold-absorbing!

【Pharmaceutical Network Market Analysis】Up to now, the third quarterly report of A-share pharmaceutical and biological listed companies has ended ((Shenwan Industry Classification, the same below)).

In the first three quarters of this year, the industry achieved a total operating income of 1.
82 trillion yuan, a year-on-year increase of 9.
91%; The net profit attributable to the shareholders of the parent company was 195.
925 billion yuan, a year-on-year increase of 8.
14%.

A total of more than 40% of the companies achieved both revenue and net profit growth, and the overall performance was good
.
On the subdivision track (according to the secondary industry classification of Shenwan), head enterprises such as medical services and medical devices are obviously more gold-absorbing
.
From the perspective of year-on-year revenue growth in the first three quarters of this year, medical services, medical devices, biological products, pharmaceutical business and other subdivisions performed well
.
Among them, the operating income of the leading biopharmaceutical enterprise Shenzhou Cell in the first three quarters increased by more than 63 times year-on-year, and the company's third quarterly report showed that the operating income from January to September was 650 million yuan, a year-on-year increase of 6373.
79%.

It is understood that in July 2021, the first product of China Cell, Anjia, was approved for listing and began to generate sales revenue, and the company's current revenue comes from the sales revenue
of this product.
Anjiain is the first domestic recombinant factor 8 product, mainly used for the treatment of rare disease hemophilia A, and can only be used for the control and prevention
of bleeding in domestic adults and adolescents (≥ 12 years old) hemophilia A (congenital coagulation factor VIII deficiency).
The field of in vitro diagnostics also performed very well, with at least 40 companies growing
their operating income year-on-year.
Among them, the revenue growth rate of the leading enterprise Jiuan Medical in the first three quarters reached 3010.
77%, and the revenue growth rate of Mentor Biologics, Ahuilong, Kaipu Biologics and other companies in the first three quarters reached 285.
38%, 265.
06% and 113.
82%
respectively.
The analysis believes that these companies with outstanding performance currently have overseas business layouts, among which Anxu Biologics, Altai Biologics and other enterprises have deeply benefited from overseas layout
.
The third quarterly report shows that the operating income of Anxu Biotechnology in the first nine months increased by 798.
35% year-on-year; Altai's operating income increased by 201.
96%
year-on-year.
From the perspective of net profit growth in the first three quarters of this year, after excluding companies with net profit losses attributable to the parent in the same period of the year, a total of 18 companies doubled their net profits in the first three quarters, and 39 companies doubled
their net profits in the third quarter year-on-year.
The outstanding performance of in vitro diagnostic head Jiuan Medical, CXO head Wise Pharmaceutical, IVD head Anxu Biotechnology, etc.
, the net profit growth rate was 31918.
64%, 6799.
35% and 1003.
25%
respectively.
In addition, the net profit growth rate of many leading companies including Shanghai Yizhong, Dongbao Biotechnology, Yahuilong, Northeast Pharmaceutical, Jiaying Pharmaceutical and so on exceeded 300%.

Overall, the outstanding performance is in vitro diagnostic sector
.
In the first three quarters of this year, the overall revenue of the sector continued to grow rapidly, mainly due to the large demand
for antigen and nucleic acid testing at home and abroad.
Zhongtai Securities expects that IVD routine business is expected to gradually resume after the normalization of the epidemic, and the recent in vitro diagnostic centralized procurement policy tends to ease, combined with policy trends, competition pattern, epidemic progress, etc.
, optimistic about 4 investment directions: IVD innovative technology platform, third-party medical laboratory, in vitro diagnostic upstream, in vitro diagnosis overseas, the head enterprises on the relevant track are worth paying attention to
.
Looking forward to the future market, some institutions predict that in 2022, the size of China's in vitro diagnostic market is expected to reach 146 billion yuan, with an average annual compound growth rate of 17.
8%
from 2019 to 2024.
Some institutions believe that with the acceleration of aging, the in vitro diagnostic industry may become a just-in-demand industry, and the scale is expected to grow to 288.
15 billion yuan by 2030, with huge
market prospects.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.